Astec Lifesciences Limited

Astec Lifesciences Limited

672.60
INR
+2.15
(+0.32%)
-34.77EPS
15.87BMarket Cap
Oct 26Next Earn
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
2026 Y
TTM
Revenue per Share
112.22
141.79
118.84
149.86
183.66
218.78
265.12
281.3
342.74
318.01
231.66
192.82
208.17
211.85
Basic EPS, GAAP
4.7
7.85
2.53
9.73
17.74
18.14
24.1
32.98
45.52
12.94
-23.75
-68.71
-37.79
-34.79
Free Cash Flow per Basic Share
-2.42
-6.71
-19.67
-0.84
7.61
-19.03
62.47
-56.12
-40.72
-21.57
-63.41
-15.41
-40.28
- -
Dividend per Share
0.85
1.15
1.49
- -
1.79
1.79
1.49
1.49
1.49
1.49
1.49
- -
- -
- -
Book Value per Share
60.78
58.91
60.21
70.2
86.22
102.77
125.05
156.65
200.78
212.28
186.89
118.79
175.3
- -
Tangible Book Value per Share
59.91
57.27
58.52
68.41
84.76
101.55
123.24
154.03
195.01
204.22
177.07
106.92
164.19
- -
Basic Weighted Avg Shares
18
19
20
20
20
20
20
20
20
20
20
20
21
22
Sales/Revenue/Turnover
2,070
2,669
2,330
2,944
3,613
4,309
5,226
5,549
6,766
6,282
4,577
3,781
4,457
4,580
Operating Margin (%)
9.98
16.02
10.26
17.33
15.62
15.9
14.25
16.17
17.79
6.93
-9.09
-28.9
-11.08
-9.62
Depreciation Expense
148
127
104
137
147
193
232
257
344
337
363
437
449
456
Net Income, GAAP
87
148
50
191
349
357
475
650
899
256
-469
-1,348
-809
-752
Effective Tax Rate (%)
22.41
- -
59.22
33.28
37.11
36.02
22.53
26.95
25.79
26.76
- -
- -
- -
- -
Profit Margin (%)
4.19
5.54
2.13
6.49
9.66
8.29
9.09
11.72
13.28
4.07
-10.25
-35.63
-18.15
-16.42
Working Capital
177
47
-118
47
-67
-3
134
82
251
-273
13
-246
-568
- -
LT Debt
181
127
82
4
2
- -
- -
400
- -
109
1,990
2,800
500
- -
Total Equity
1,135
1,155
1,181
1,382
1,699
2,028
2,469
3,093
3,967
4,196
3,695
2,350
3,909
- -
Return on Invested Capital (%)
4.76
- -
-3.21
10.55
13.63
12.57
14.59
15.62
15.49
4.4
- -
- -
- -
- -
Return on Capital (%)
8.17
- -
4.58
10.87
14.83
12.97
15.81
16.27
16.42
5.61
- -
- -
- -
- -
Return on Common Equity (%)
7.91
12.91
4.25
14.93
22.69
19.21
21.16
23.41
25.47
6.27
-11.9
-44.62
-25.88
- -

Capital Structure

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
ST Debt
- -
3,989
- -
LT Borrowings
- -
500
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
22
22
22
Market Capitalization
15,714
12,019
15,870

Working Capital

INR

•

in mil. unless spec.
Dec'26
Mar'26
Jun'27
Total Current Assets
- -
4,430
- -
Cash, Cash Equivalents & STI
- -
105
- -
Accounts Receivable, Net
- -
2,477
- -
Inventories
- -
1,380
- -
Total Current Liabilities
- -
4,998
- -
Payables & Accruals
- -
- -
- -
ST Debt
- -
3,989
- -
Deferred Revenue
- -
- -
- -

Growth Rates

INR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
15.83%
10.4%
66.34%
Free Cash Flow
-183.92%
45.84%
185.38%
Net Income, GAAP
27%
-33.96%
-39.95%
Sales/Revenue/Turnover
8.39%
-2.37%
17.87%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
694
985
939
1,195
3,781
2026
911
- -
1,247
1,586
4,457
2027
836
- -
- -
- -
- -

Quarterly Earnings Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
-20.11
-19.66
-20.59
-8.2
-68.71
2026
-16.85
- -
-7.04
-3.48
-37.79
2027
-8.4
- -
- -
- -
- -

Quarterly Dividends Per Share

INR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2025
- -
- -
- -
- -
- -
2026
- -
- -
- -
- -
- -
2027
- -
- -
- -
- -
- -

Company Description

CEO
Anurag Roy
Full Time Employees
716
Sector
Process industries
Industry
Chemicals: agricultural
Address
Godrej One Mumbai MH India 400079
IPO Date
Nov 25, 2009
Business
Astec LifeSciences Limited Astec LifeSciences Limited manufactures agrochemical active ingredients including triazole fungicides such as Flutriafol, Prothiaconazole, Metalaxyl, and Cyproconazole; herbicides like Azimsulfuron, Halosulfuron, and Rimsulfuron; insecticides such as Transfluthrin; and growth regulators including Tribenuron methyl, alongside pharmaceutical intermediates, bulk formulations, specialty chemicals, and contract development and manufacturing organization services for global agrochemical innovators. The company, founded in 1994 and headquartered in Mumbai, India, operates approximately nine manufacturing plants in Maharashtra, with a sales mix split between domestic Indian markets and exports to over 17 countries across North America, Europe, West Asia, South-East Asia, Latin America, Africa, and Australia. A subsidiary of Godrej Agrovet Limited, it serves the agricultural chemicals industry through a single Agrochemicals segment, focusing on technical actives, intermediates, and custom manufacturing for crop protection and pharmaceutical applications. Recent developments include the inauguration of an advanced R&D center in Rabale, Maharashtra, in 2023 with a US$1.4 million investment to enhance innovation and CDMO capabilities; board approval in October 2025 for re-appointments of independent directors Nandkumar Dhekne and Anjali Gupte, along with related party transactions exceeding materiality thresholds with holding company Godrej Agrovet Limited for FY2025-26; a rights issue announced in June 2025 to raise up to INR2.50 billion, with details finalized for 28,01,673 shares amounting to Rs 249.35 crores as of November 2025; and a strategic shift toward global CDMO partnerships highlighted at Chemspec Europe 2025, including substantial investments in R&D and manufacturing over the past two years.